ArticleBMC cancer2008
Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines.
Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management.iScience · 2024Review
- Emerging biomarker in carcinogenesis. Focus on Nestin.Postepy dermatologii i alergologii · 2022Review
- Serotonin limits generation of chromaffin cells during adrenal organ development.Nature communications · 2022Article
- Enhanced Antiproliferative Effect of Combined Treatment with Calcitriol and All-International journal of molecular sciences · 2020Article
- TREX1 suppression imparts cancer-stem-cell-like characteristics to CD133International journal of clinical and experimental pathology · 2019Article
- Novel molecular insights and new therapeutic strategies in osteosarcoma.Cancer cell international · 2018Review
- Establishment and characterization of human osteosarcoma cells resistant to pyropheophorbide-α methyl ester-mediated photodynamic therapy.International journal of oncology · 2017Article
- Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.Cancer biomarkers : section A of Disease markers · 2016Article
- Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells.Stem cells international · 2016Review
- Non-DHFR-mediated effects of methotrexate in osteosarcoma cell lines: epigenetic alterations and enhanced cell differentiation.Cancer cell international · 2016Article
- Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines.International journal of molecular medicine · 2015Article
- Nestin as a marker of cancer stem cells.Cancer science · 2015Review
- Characterization of Nestin, a Selective Marker for Bone Marrow Derived Mesenchymal Stem Cells.Stem cells international · 2015Review
- Increased Oxidative Stress as a Selective Anticancer Therapy.Oxidative medicine and cellular longevity · 2015Review
- LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Osteosarcoma: mouse models, cell of origin and cancer stem cell.Postdoc journal : a journal of postdoctoral research and postdoctoral affairs · 2014Article
- CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study.Experimental and therapeutic medicine · 2012Article
- Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.PloS one · 2012Article
- Cancer Stem Cells and Pediatric Solid Tumors.Cancers · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNestin was originally identified as a class VI intermediate filament protein that is expressed in stem cells and progenitor cells in the mammalian CNS during development. This protein is replaced in the adult organism by other intermediate filament proteins; however, nestin may be re-expressed under certain pathological conditions such as ischemia, inflammation, brain injury, and neoplastic transformation. Nestin has been detected in many kinds of tumors, especially in tumors derived from the CNS. Co-expression of nestin and the CD133 surface molecule is considered to be a marker for cancer stem cells in neurogenic tumors. Our work was aimed at a detailed study of nestin expression in osteosarcomas and osteosarcoma-derived cell lines.
methodsUsing immunodetection methods, we examined nestin in tumor tissue samples from 18 patients with osteosarcomas. We also successfully established permanent cell lines from the tumor tissue of 4 patients and immunodetection of nestin and CD133 was performed on these cell lines.
resultsNestin-positive tumor cells were immunohistochemically detected in all of the examined osteosarcomas, but the proportion of these cells that were positively stained as well as the intensity of staining varied. Nestin-positive cells were rarely observed in 2 tumor samples, and the remaining 16 tumor samples showed various nestin expression patterns ranging from very sporadic occurrence to an overwhelming proportion of cells with strong positive staining. Three of the established osteosarcoma cell lines were demonstrated to be nestin-positive, and only one cell line showed no expression of nestin; this finding corresponds with the rare occurrence of nestin-positive cells in the respective tumor sample. Moreover, three of these osteosarcoma cell lines were undoubtedly proven to be Nes+/CD133+.
conclusionOur results represent the first evidence of nestin expression in osteosarcomas and suggest the possible occurrence of cells with a stem-like phenotype in these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.